Nucana Plc ADR (NCNA)

$1.03 -0.08 (-7.21%)
Market Cap 2.83M
Revenue (ttm) 0.00
Net Income (ttm) -34.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 42,100
Avg Vol 150,664
Day's Range N/A - N/A
Shares Out 2.64M
Stochastic %K 25%
Beta 0.97
Analysts Sell
Price Target $25.00

Latest News on NCNA

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 25, 2024, 7:00 AM EST - 2 months ago

NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Nov 11, 2024, 7:00 AM EST - 2 months ago

NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

Oct 4, 2024, 12:03 PM EDT - 4 months ago

Baillie Gifford's Strategic Acquisition of NuCana PLC Shares

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

Sep 25, 2024, 4:01 PM EDT - 4 months ago

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Sep 14, 2024, 3:01 AM EDT - 4 months ago

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

Aug 29, 2024, 4:01 PM EDT - 5 months ago

NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 4:01 PM EDT - 6 months ago

NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Global Healthcare Conference

May 30, 2024, 8:36 AM EDT - 8 months ago

NuCana to Present at the Jefferies Global Healthcare Conference

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

May 21, 2024, 8:00 AM EDT - 9 months ago

NuCana to Present at TD Cowen's 5th Annual Oncology Innovation Summit

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

May 16, 2024, 4:01 PM EDT - 9 months ago

NuCana Reports First Quarter 2024 Financial Results and Provides Business Update

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 1, 2024, 4:01 PM EDT - 9 months ago

NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

Apr 9, 2024, 4:30 PM EDT - 10 months ago

NuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical Study

NuCana Announces Plan to Implement ADS Ratio Change

Mar 27, 2024, 4:30 PM EDT - 11 months ago

NuCana Announces Plan to Implement ADS Ratio Change

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

Mar 20, 2024, 4:01 PM EDT - 11 months ago

NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

Feb 27, 2024, 8:00 AM EST - 1 year ago

NuCana to Present at TD Cowen's 44th Annual Health Care Conference

NuCana: Potential Turnaround In 2024 But Risky

Jan 3, 2024, 2:39 AM EST - 1 year ago

NuCana: Potential Turnaround In 2024 But Risky

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 16, 2023, 4:01 PM EST - 1 year ago

NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Listing Transfer to Nasdaq Capital Market

Nov 10, 2023, 4:01 PM EST - 1 year ago

NuCana Announces Listing Transfer to Nasdaq Capital Market

NuCana to Present at the Jefferies London Healthcare Conference

Nov 8, 2023, 4:01 PM EST - 1 year ago

NuCana to Present at the Jefferies London Healthcare Conference

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

Nov 1, 2023, 4:01 PM EDT - 1 year ago

NuCana to Participate in the Truist Securities 2023 BioPharma Symposium

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 16, 2023, 7:00 AM EDT - 1 year ago

NuCana Presents Promising Data on NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Oct 13, 2023, 12:30 PM EDT - 1 year ago

NuCana Presents Encouraging Data on NUC-3373 in Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

Sep 18, 2023, 8:00 AM EDT - 1 year ago

NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 16, 2023, 4:01 PM EDT - 1 year ago

NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update

NuCana to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 1 year ago

NuCana to Present at the Jefferies Healthcare Conference

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

May 17, 2023, 4:01 PM EDT - 1 year ago

NuCana Reports First Quarter 2023 Financial Results and Provides Business Update

NuCana Announces Receipt of Nasdaq Notice

May 12, 2023, 4:01 PM EDT - 1 year ago

NuCana Announces Receipt of Nasdaq Notice

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

Apr 14, 2023, 8:00 AM EDT - 1 year ago

NuCana Presents Data at the AACR 2023 Annual Meeting Highlighting Novel NUC-7738 Mechanisms of Action

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Apr 4, 2023, 4:01 PM EDT - 1 year ago

NuCana Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

Mar 24, 2023, 4:30 PM EDT - 2 years ago

Technical Board of Appeal of the European Patent Office Issues Oral Ruling that NuCana's ‘190 Patent is Not Valid

NuCana to Participate in Two Upcoming Investor Conferences

Feb 28, 2023, 8:00 AM EST - 2 years ago

NuCana to Participate in Two Upcoming Investor Conferences

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

Jan 8, 2023, 4:30 AM EST - 2 years ago

NuCana: Pipeline And Major Gilead Litigation Progressing Nicely

NuCana Announces Receipt of NASDAQ Notice

Jan 6, 2023, 4:01 PM EST - 2 years ago

NuCana Announces Receipt of NASDAQ Notice

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

Nov 16, 2022, 4:01 PM EST - 2 years ago

NuCana Reports Third Quarter 2022 Financial Results and Provides Business Update

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

Oct 26, 2022, 7:00 AM EDT - 2 years ago

NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 22, 2022, 3:40 PM EDT - 2 years ago

NuCana: An Intriguing 'Sum Of The Parts' Story

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

Sep 12, 2022, 10:45 AM EDT - 2 years ago

NuCana Presents Promising Data on NUC-7738 at the European Society of Medical Oncology (ESMO) Annual Meeting 2022

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

Sep 6, 2022, 8:00 AM EDT - 2 years ago

NuCana Announces Presentations at the European Society for Medical Oncology (ESMO) Congress 2022

NuCana to Participate in Citi's 17th Annual BioPharma Conference

Aug 31, 2022, 8:00 AM EDT - 2 years ago

NuCana to Participate in Citi's 17th Annual BioPharma Conference

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 17, 2022, 4:01 PM EDT - 2 years ago

NuCana Reports Second Quarter 2022 Financial Results and Provides Business Update

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Jul 13, 2022, 6:00 AM EDT - 2 years ago

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Why NuCana Shares Are Rising Today?

Jul 11, 2022, 1:52 PM EDT - 2 years ago

Why NuCana Shares Are Rising Today?

German Court Rules that Gilead's Sofosbuvir Infringes NuCana's ‘190 Patent

Jul 11, 2022, 8:00 AM EDT - 2 years ago

German Court Rules that Gilead's Sofosbuvir Infringes NuCana's ‘190 Patent

NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

Jun 10, 2022, 7:00 AM EDT - 2 years ago

NuCana Announces Presentation on NUC-7738 at the European Hematology Association (EHA) 2022 Hybrid Congress

NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

Jun 2, 2022, 4:01 PM EDT - 2 years ago

NuCana Reports First Quarter 2022 Financial Results and Provides Business Update

NuCana to Participate in the 2022 Jefferies Healthcare Conference

Jun 1, 2022, 4:01 PM EDT - 2 years ago

NuCana to Participate in the 2022 Jefferies Healthcare Conference

NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update

Apr 27, 2022, 4:01 PM EDT - 3 years ago

NuCana Reports Fourth Quarter and Year Ended 2021 Financial Results and Provides Business Update

NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022

Mar 8, 2022, 4:35 PM EST - 3 years ago

NuCana Announces Upcoming Presentations on NUC-3373 at the American Association for Cancer Research (AACR) Annual Meeting 2022

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

Mar 2, 2022, 4:01 PM EST - 3 years ago

NuCana Announces Update for Phase 3 Biliary Tract Cancer Study

NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study

Feb 22, 2022, 4:01 PM EST - 3 years ago

NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study